Suppr超能文献

间充质干细胞作为心血管再生的未来治疗方法及其面临的挑战。

Mesenchymal stem cells as future treatment for cardiovascular regeneration and its challenges.

作者信息

Seow Ke Sin, Ling Anna Pick Kiong

机构信息

Division of Applied Biomedical Sciences and Biotechnology, School of Health Sciences, International Medical University, Kuala Lumpur, Malaysia.

出版信息

Ann Transl Med. 2024 Aug 1;12(4):73. doi: 10.21037/atm-23-1936. Epub 2023 Dec 29.

Abstract

Cardiovascular diseases (CVDs), particularly stroke and myocardial infarction (MI) contributed to the leading cause of death annually among the chronic diseases globally. Despite the advancement of technology, the current available treatments mainly served as palliative care but not treating the diseases. However, the discovery of mesenchymal stem cells (MSCs) had gained a consideration to serve as promising strategy in treating CVDs. Recent evidence also showed that MSCs are the strong candidate to be used as stem cell therapy involving cardiovascular regeneration due to its cardiomyogenesis, anti-inflammatory and immunomodulatory properties, antifibrotic effects and neovascularization capacity. Besides, MSCs could be used for cellular cardiomyoplasty with its transdifferentiation of MSCs into cardiomyocytes, paracrine effects, microvesicles and exosomes as well as mitochondrial transfer. The safety and efficacy of utilizing MSCs have been described in well-established preclinical and clinical studies in which the accomplishment of MSCs transplantation resulted in further improvement of the cardiac function. Tissue engineering could enhance the desired properties and therapeutic effects of MSCs in cardiovascular regeneration by genome-editing, facilitating the cell delivery and retention, biomaterials-based scaffold, and three-dimensional (3D)-bioprinting. However, there are still obstacles in the use of MSCs due to the complexity and versatility of MSCs, low retention rate, route of administration and the ethical and safety issues of the use of MSCs. The aim of this review is to highlight the details of therapeutic properties of MSCs in treating CVDs, strategies to facilitate the therapeutic effects of MSCs through tissue engineering and the challenges faced using MSCs. A comprehensive review has been done through PubMed and National Center for Biotechnology Information (NCBI) from the year of 2010 to 2021 based on some specific key terms such as 'mesenchymal stem cells in cardiovascular disease', 'mesenchymal stem cells in cardiac regeneration', 'mesenchymal stem cells facilitate cardiac repairs', 'tissue engineering of MSCs' to include relevant literature in this review.

摘要

心血管疾病(CVDs),尤其是中风和心肌梗死(MI),是全球慢性病中每年导致死亡的主要原因。尽管技术不断进步,但目前可用的治疗方法主要是姑息治疗,而非治疗疾病本身。然而,间充质干细胞(MSCs)的发现为治疗心血管疾病提供了一种有前景的策略。最近的证据还表明,由于其心肌生成、抗炎和免疫调节特性、抗纤维化作用以及血管新生能力,MSCs是用于心血管再生的干细胞治疗的有力候选者。此外,MSCs可通过其向心肌细胞的转分化、旁分泌作用、微泡和外泌体以及线粒体转移用于细胞心肌成形术。在成熟的临床前和临床研究中已经描述了利用MSCs的安全性和有效性,其中MSCs移植的成功导致心脏功能的进一步改善。组织工程可以通过基因组编辑、促进细胞递送和保留、基于生物材料的支架以及三维(3D)生物打印来增强MSCs在心血管再生中的理想特性和治疗效果。然而,由于MSCs的复杂性和多功能性、低保留率、给药途径以及使用MSCs的伦理和安全问题,在使用MSCs方面仍然存在障碍。本综述的目的是强调MSCs在治疗心血管疾病中的治疗特性细节、通过组织工程促进MSCs治疗效果的策略以及使用MSCs所面临的挑战。基于一些特定的关键词,如“心血管疾病中的间充质干细胞”、“心脏再生中的间充质干细胞”、“间充质干细胞促进心脏修复”、“MSCs的组织工程”,通过PubMed和美国国立生物技术信息中心(NCBI)对2010年至2021年期间的文献进行了全面综述,以纳入本综述中的相关文献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e80b/11304428/22753a6e845e/atm-12-04-73-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验